ARTICLE | Company News
Genentech, ImmunoGen in second antibody deal
May 8, 2000 7:00 AM UTC
The five-year deal allows DNA to use IMGN's maytansinoid Tumor- Activated Prodrug (TAP) technology in DNA's antibody research program. DNA also has an option to obtain exclusive product licenses for a...